Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Clinical, biochemical, and molecular analysis of combined methylmalonic acidemia and hyperhomocysteinemia (cblC type) in China.
[homocystinuria without methylmalonic aciduria]
The
most
common
inborn
error
of
cobalamin
(
cbl
)
metabolism
in
China
is
the
cblC
type
characterized
by
combined
methylmalonic
acidemia
and
hyperhomocysteinemia
.
The
clinical
presentation
is
relatively
nonspecific
,
such
as
feeding
difficulty
,
recurrent
vomiting
,
hypotonia
,
lethargy
,
seizures
,
progressive
developmental
delay
,
and
mental
retardation
,
together
with
anemia
and
metabolic
acidosis
.
More
specific
biochemical
findings
include
high
levels
of
propionylcarnitine
(
C
3
)
,
free
carnitine
(
C
3
/
C
0
)
,
and
acetylcarnitine
(
C
3
/
C
2
)
measured
by
tandem
mass
spectrometry
(
MS
/
MS
)
,
elevation
of
methylmalonic
acid
(
MMA
)
measured
by
gas
chromatography-mass
spectrometry
(
GC
-
MS
)
,
and
increased
total
homocysteine
with
normal
or
decreased
methionine
.
We
report
on
50
Chinese
patients
with
combined
methylmalonic
acidemia
and
hyperhomocysteinemia
.
Forty
-
six
belonged
to
the
cblC
complementation
group
.
Mutation
analysis
of
the
MMACHC
gene
was
performed
to
characterize
the
mutational
spectrum
of
cblC
deficiency
,
and
17
different
mutations
were
found
.
Most
were
clustered
in
exons
3
and
4
,
accounting
for
91
.
3
%
of
all
mutant
alleles
.
Two
mutations
were
novel
,
namely
,
c
.
315
Â
C
>
G
(
p
.
Y
105
X
)
and
c
.
470
Â
G
>
C
(
p
.
W
157
S
)
.
In
terms
of
genotype-phenotype
correlation
,
the
c
.
609
Â
G
>
A
mutation
was
associated
with
early
-onset
disease
when
homozygous
.
Unlike
previous
reports
from
other
populations
,
c
.
609
Â
G
>
A
(
p
.
W
203
X
)
was
the
most
frequent
cblC
mutation
detected
in
our
study
of
Chinese
patients
,
affecting
51
of
92
MMACHC
alleles
(
55
.
4
%
)
.
The
high
prevalence
of
this
nonsense
mutation
could
have
potential
therapeutic
significance
for
Chinese
cblC
patients
.
Besides
traditional
approaches
consisting
of
hydroxocobalamin
injections
,
carnitine
,
betaine
,
and
protein
restriction
,
novel
drugs
that
target
premature
termination
codons
may
have
a
role
in
the
future
.
Diseases
Validation
Diseases presenting
"high levels"
symptom
22q11.2 deletion syndrome
adrenal incidentaloma
allergic bronchopulmonary aspergillosis
alpha-thalassemia
aromatase deficiency
cadasil
canavan disease
classical phenylketonuria
congenital adrenal hyperplasia
congenital toxoplasmosis
cutaneous mastocytosis
cystinuria
dentin dysplasia
dentinogenesis imperfecta
dracunculiasis
dystrophic epidermolysis bullosa
erythropoietic protoporphyria
gm1 gangliosidosis
hereditary cerebral hemorrhage with amyloidosis
holt-oram syndrome
homocystinuria without methylmalonic aciduria
kabuki syndrome
kallmann syndrome
liposarcoma
papillon-lefèvre syndrome
phenylketonuria
primary effusion lymphoma
primary hyperoxaluria type 1
scrub typhus
severe combined immunodeficiency
systemic capillary leak syndrome
triple a syndrome
von hippel-lindau disease
werner syndrome
wiskott-aldrich syndrome
wolf-hirschhorn syndrome
x-linked adrenoleukodystrophy
zellweger syndrome
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom